Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for prevention of episodic migraine
NCT05028569Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin in episodic migraine (4 arms), sponsored by AbbVie Inc. Primary endpoints: Change From Baseline in the Frequency of Monthly Migraine Days Across Months 5 and 6 at 6 months and Number of Participants With Treatment-Emergent Adverse Events at 48 weeks. Started Nov 2021; status: terminated.
02
Drugs
botulinum toxin
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT05028569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028569.